DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Fluoxetine is a drug marketed by Sun Pharm Industries, Watson Labs, Barr, Dr Reddys Labs Ltd, Alembic Pharms Ltd, Ani Pharms Inc, Apnar Pharma Lp, Aurobindo Pharma, Beximco Pharms Usa, Cadila Pharms Ltd, Carlsbad, Celltrion, Cr Double Crane, Heritage Pharms Inc, Ivax Sub Teva Pharms, Landela Pharm, Marksans Pharma, Mylan, Mylan Pharms Inc, Par Pharm, Sandoz, Sciegen Pharms Inc, Specgx Llc, Sun Pharm Inds Ltd, Teva, Teva Pharms Usa, Actavis Mid Atlantic, Aurobindo Pharma Ltd, Hi Tech Pharma, Lannett Co Inc, Nostrum Labs Inc, Pharm Assoc, Wockhardt Bio Ag, Alvogen, Fosun Pharma, G And W Labs Inc, Inventia Hlthcare, Lupin Ltd, Par Form, Par Pharm Inc, Taro, Torrent, and Upsher Smith Labs. and is included in sixty-two NDAs.
The generic ingredient in FLUOXETINE is fluoxetine hydrochloride. There are twenty-seven drug master file entries for this compound. Sixty-one suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride profile page.
A generic version of FLUOXETINE was approved as fluoxetine hydrochloride by APNAR PHARMA LP on August 2nd, 2001.
Summary for FLUOXETINE
Recent Clinical Trials for FLUOXETINE
Identify potential brand extensions & 505(b)(2) entrants
|University of Toledo Health Science Campus||Phase 4|
|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||N/A|